Optimizing External Beam Radiotherapy as per the Risk Group of Localized Prostate Cancer: A Nationwide Multi-Institutional Study (KROG 18-15)

Seo Hee Choi 1,2,†, Young Seok Kim 3,†, Jesang Yu 3, Taek-Keun Nam 4, Jae-Sung Kim 5, Bum-Sup Jang 5, Jin Ho Kim 6, Youngkyong Kim 7, Bae Kwon Jeong 8, Ah Ram Chang 9, Young-Hee Park 9, Sung Uk Lee 10, Kwan Ho Cho 10, Jin Hee Kim 11, Hun Jung Kim 12, Youngmin Choi 13, Yeon Jo Kim 3,14,†, Dong Soo Lee 15, Young Ju Shin 16, Su Jung Shim 17, Won Park 18,* and Jaeho Cho 2,*

1 Department of Radiation Oncology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin 16995, Korea; clickby_si@yuhs.ac
2 Yonsei Cancer Center, Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, Korea
3 Asan Medical Center, Department of Radiation Oncology, University of Ulsan College of Medicine, Seoul 05505, Korea; ysk@amc.seoul.kr (Y.S.K.); dfjinjoy@naver.com (J.Y.); kamea1004@naver.com (Y.J.K.)
4 Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University College of Medicine, Gwangju 61469, Korea; talknam@chonnam.ac.kr
5 Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea; jskim@snubh.org (J.-S.K.); jbs.radonc@snubh.org (B.-S.J.)
6 Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03808, Korea; jinhokim@snuh.org
7 Department of Radiation Oncology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul 02447, Korea; icarus070@hanmail.net
8 Department of Radiation Oncology, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju 52727, Korea; blue129@gmu.ac.kr
9 Department of Radiation Oncology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul 04401, Korea; changaram@schmc.ac.kr (A.R.C.); ybh10530@hanmail.net (Y.-H.P.)
10 The Proton Therapy Center, National Cancer Center, Research Institute and Hospital, Goyang 10408, Korea; sulee126@ncc.re.kr (S.U.L.); kwancho@ncc.re.kr (K.H.C.)
11 Keimyung University Dongsan Medical Center, Department of Radiation Oncology, Keimyung University School of Medicine, Daegu 42601, Korea; jhkim@dsmc.or.kr
12 Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine, Incheon 22332, Korea; cancerovercome@inha.ac.kr
13 Department of Radiation Oncology, Dong-A University Hospital, Dong-A University School of Medicine, Busan 49201, Korea; cymin000@dau.ac.kr
14 Department of Radiation Oncology, Kangwon National University Hospital, Chuncheon 24289, Korea
15 Department of Radiation Oncology, College of Medicine, The Catholic University of Korea, Uijeongbu 11765, Korea; dreamdoc77@catholic.ac.kr
16 Department of Radiation Oncology, Inje University Sanggye Paik Hospital, Seoul 04551, Korea; shiyj@paik.ac.kr
17 Department of Radiation Oncology, Eulji Hospital, Eulji University School of Medicine, Seoul 01830, Korea; dcrystal@eulji.ac.kr
18 Samsung Medical Center, Department of Radiation Oncology, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
* Correspondence: wonro.park@samsung.com (W.P.); jjhmd@yuhs.ac (J.C.); Tel.: +82-2-3410-2616 (W.P.); +82-2-2228-8095 (J.C.); Fax: +82-2-3410-2619 (W.P.); +82-2-2227-7823 (J.C.)
† These authors contributed equally to this paper.

Simple Summary: This multi-institutional study analyzed the patterns of care and outcomes of external beam radiotherapy (EBRT) in localized prostate cancer to identify the optimal EBRT strategy for each risk-stratified patient subgroup for clinical practice implementation. In 1573 patients from 17 institutions, EBRT treated prostate cancer effectively. Also, among various risk classification tools, NCCN classification revealed the highest predictive power. The modern RT techniques and dose escalation (≥179 Gy1.5) enhanced therapeutic effects of RT significantly, especially in the high-risk group. On the other hand, modest doses (≥170 Gy1.5) was a significant factor in the intermediate-risk
group and no significant impact of dose was observed in the low-risk group. IMRT+≥179 Gy\textsubscript{1.5}+ hypofractionation resulted in higher biochemical failure-free survival in all risk groups, and it translated into survival benefits in the high-risk group. Therefore, risk-adapted RT (more intense RT, high-risk patients; moderate-dose RT, low-risk patients) can be considered, although further prospective studies are warranted.

Abstract: Purpose: This nationwide multi-institutional study analyzed the patterns of care and outcomes of external beam radiotherapy (EBRT) in localized prostate cancer patients. We compared various risk classification tools and assessed the need for refinements in current radiotherapy (RT) schemes. Methods and Materials: We included non-metastatic prostate cancer patients treated with primary EBRT from 2001 to 2015 in this study. Data of 1573 patients from 17 institutions were analyzed and re-grouped using a risk stratification tool with the highest predictive power for biochemical failure-free survival (BCFFS). We evaluated BCFFS, overall survival (OS), and toxicity rates. Results: With a median follow-up of 75 months, 5- and 10-year BCFFS rates were 82% and 60%, and 5- and 10-year OS rates were 95% and 83%, respectively. NCCN risk classification revealed the highest predictive power (AUC = 0.556, 95% CI 0.524–0.588; \( p < 0.001 \)). Gleason score, iPSA < 12 ng/mL, intensity-modulated RT (IMRT), and ≥179 Gy\textsubscript{1.5} (EQD2, 77 Gy) were independently significant for BCFFS (all \( p < 0.05 \)). IMRT and ≥179 Gy\textsubscript{1.5} were significant factors in the high-risk group, whereas ≥170 Gy\textsubscript{1.5} (EQD2, 72 Gy) was significant in the intermediate-risk group and no significant impact of dose was observed in the low-risk group. Both BCFFS and OS improved significantly when ≥179 Gy\textsubscript{1.5} was delivered using IMRT and hypofractionation in the high-risk group without increasing toxicities. Conclusions: With NCCN risk classification, dose escalation with modern high-precision techniques might increase survivals in the high-risk group, but not in the low-risk group, although mature results of prospective studies are awaited.

Keywords: prostate cancer; radiotherapy; NCCN; risk assessment; dose-escalation; hypofractionation

1. Introduction

External-beam radiotherapy (EBRT) is a well-established local therapy for non-metastatic prostate cancer [1,2]. EBRT alone, or with other treatments, is highly effective for prolonging life and preserving quality of life. Localized prostate cancer patients can be stratified into risk groups by clinicopathological parameters. Each risk group has multiple treatment options; the superiority of different treatments remains undetermined. Since the publication of the D’Amico risk-stratification system [3], several risk-stratification tools have been proposed to facilitate treatment decisions for prostate cancer [4–7].

Traditionally, prostate cancer patients receive a 64–70 Gy EBRT dose, although no clear cutoff is recommended. Recent studies suggested these doses to be insufficient for tumor control, and dose escalation was proposed for the best biochemical control with the development of modern RT techniques [8–19]. Reports indicate that intensity-modulated radiotherapy (IMRT), which has largely replaced non-modulated three-dimensional conformal radiation therapy (3D-CRT), delivered higher radiation doses with reduced toxicity, without compromising treatment outcomes [20–22]. Since prostate cancer has a low \( \alpha/\beta \) ratio (1.5) [23], treating patients with higher doses/fraction over shorter periods (hypofractionation (HF)) using IMRT has generated increased interest [24]. Nevertheless, the optimum dose and fractionation remain unclear. Moreover, studies analyzing the effects of dose escalation with modern RT techniques in each risk group are scarce.

Our study was designed to comprehensively evaluate these gaps in the literature using a nationwide database of localized prostate cancer patients. We first compared various risk classification tools in our cohort. Ultimately, we aimed to identify the optimal EBRT strategy for each risk-stratified patient subgroup and to identify risk-adapted treatment policies for clinical practice implementation.
2. Materials and Methods

2.1. Patient Selection

Patients with histologically confirmed non-metastatic prostate cancer who underwent definitive EBRT in Korea (January 2001 to December 2015) were eligible for this study. Patients with <3 years’ follow-up, insufficient EBRT data, salvage RT for any recurrence, or previous pelvic irradiation, prostate brachytherapy, or cytotoxic chemotherapy were excluded. The database included 1573 patients’ data from 17 different institutions. We reviewed medical charts and analyzed disease status, treatment, and outcomes.

All patients were re-grouped into risk subgroups per the following risk-stratification tools: National Comprehensive Cancer Network (NCCN) [4], D’Amico [3], American Urological Association (AUA) [5], and Cambridge Prognostic Groups (CPG) risk group systems [6]. Table S1 describes these tools. We selected the tool that exhibited the highest predictive power for our data and classified all patients into low-, intermediate-, and high-risk groups according to the risk classification.

The Korean Radiation Oncology Group (KROG) authorized and cooperated with this study (named “KROG 18-15”). The institutional review boards of each participating hospital approved KROG 18-15. Since the study was retrospective, the need for written informed consent was waived.

2.2. Treatment and Follow-Up

All patients underwent EBRT. The techniques and doses were determined by the attending radiation oncologists. RT techniques included 3D-CRT, IMRT, and proton beam therapy. The dose fractionation scheme included conventional fractionation (CF) (1.8–2 Gy/fraction), moderate-HF (>2 Gy/fraction), and ultra-HF (≥5 Gy/fraction). To adjust for different dose fractionation, we calculated the biologically effective dose (BED) with prostate cancer α/β ratio of 1.5. Concerning the RT field, most patients received radiation to the prostate (± seminal vesicle); the whole pelvis was added for some patients with adverse features. Androgen deprivation therapy (ADT) was administered with RT or before the referral for RT. Treatment guidelines for each risk group regulated the ADT protocol. Briefly, in patients in the unfavorable intermediate-risk, high-risk, and very-high-risk groups, hormone therapy was administered first, unless there were contraindications. The duration of ADT was usually 2 to 6 months in the low/intermediate-risk group. In some patients, 2 months of neoadjuvant ADT was performed before the start of RT. The duration was longer (usually 2 to 3 years) in the high/very-high-risk group. Also, neoadjuvant ADT (within 6 months) was performed in some patients. However, ADT duration was usually determined according to changes in PSA levels, and there were differences in each institution’s policies. The attending physician (mainly, urologists) of each institution determined ADT maintenance duration and regimen.

Per institutional protocols, patients were followed up after RT completion at 4–6 weeks, 3–6 monthly until the end of year 2, and 6–12 monthly thereafter. Prostate-specific antigen (PSA) measurement was performed at every follow-up. Bone scintigraphy and/or computerized tomography scans were performed to identify distant metastases including lymph node metastasis, if clinically indicated. PSA relapse was defined using the Phoenix definition (nadir + 2 ng/mL). ADT was reinitiated if PSA was persistently elevated after RT in some patients even though PSA was not nadir + 2 ng/mL. Therefore, biochemical failure (BCF) was defined as nadir + 2 ng/mL or ADT initiation for persistently elevated PSA. Clinical failure included any type of disease progression diagnosed by radiological/histological examinations. Radiation-related lower gastrointestinal (GI) or genitourinary (GU) toxicity was assessed during RT, the first month after RT, and subsequently at 3- to 6-month intervals (Radiation Therapy Oncology Group radiation toxicity criteria). Events occurring within and 3 months post-RT were classified as acute and late toxicities, respectively.
2.3. Statistical Analysis

The primary endpoint was BCF-free survival (BCFFS): the interval between the date of diagnosis and the date of BCF or last follow-up. The secondary endpoints were the overall survival (OS) and cancer-specific survival rates. The OS rate was defined as the time from the date of diagnosis to death due to any cause or the last follow-up. The cancer-specific survival rate only accounted for deaths due to prostate cancer. Survival rates were estimated using the Kaplan–Meier method. To identify the highest predictive power among the risk-grouping systems, we generated receiver operating characteristic curves for BCFFS in each system and estimated the area under the curve (AUC). The prognostic impact of clinical or RT-related factors was analyzed (log-rank test, categorical variables; logistic regression analysis, continuous variables) in all patients or in each risk subgroup. All variables that showed statistical significance in univariate analyses were entered into multivariate analyses using a Cox proportional hazard model. The most significant radiation dose (Gy) cutoff was determined by categorizing prescribed doses per patient into two groups using the cutoff point with the highest Youden’s index value, and the patients were divided into “high-dose” and “low-dose” groups. Other subgroup characteristics were compared using Pearson χ² test, Fisher exact test, and Student’s t-test. p-values < 0.05 denoted statistical significance. Furthermore, we used propensity score matching to estimate the average marginal effect of RT modality (3D vs. IMRT/proton) on those who received it, accounting for confounding by the included covariates. We performed 1:1 nearest-neighbor propensity score matching without replacement with a propensity score estimated using logistic regression of the treatment on the covariates. After matching, we confirmed that all standardized mean differences for the covariates were below 0.1 and that all standardized mean differences for squares and two-way interactions between covariates were below 0.15, indicating adequate balance. The propensity score was estimated using logistic regression of the RT modality (3D vs. IMRT/proton) on the covariates. We conducted propensity score matching using the Matchit package in R [25]. All other analyses were performed using SPSS version 25.0 (IBM Inc., Armonk, NY, USA).

3. Results

3.1. Patient Characteristics

From 2001 to 2015, we enrolled 1573 patients per the inclusion criteria. Each risk group had the following number of patients: (1) NCCN: low, 177; intermediate, 408; high, 761; very high, 227. (2) D’Amico: low, 177; intermediate, 383; high, 1013. (3) AUA: low, 177; intermediate, 539; high, 857. (4) CPG: low, 178; intermediate, 407; high, 366; very high, 622. In total, 63% received ADT before RT and/or concurrently. Concurrent ADT was performed in 61% NCCN high-risk group patients and 55% NCCN very high-risk group patients. Whole pelvis RT (WPRT) was performed in 34% of patients, predominantly in high-risk patients (NCCN high risk 47%; NCCN very high risk, 53%). With regards to RT modality, 3D-CRT, IMRT, and proton therapy were performed in 24%, 74%, and 3% of patients, respectively. With regards to RT dose scheme, conventional fractionation, HF; and ultra-HF were selected for 44%, 47%, and 9% of patients, respectively. The median total irradiated dose was 179.1 (range, 107.3–225.0) Gy₁.₅. Significantly higher doses were delivered with the selection of more hypofractionated schedules (Dmean: conventional, 167.9 Gy; HF, 185.5 Gy; and ultra-HF, 214.9 Gy; p < 0.001) (Figure S1a) or more modern RT techniques (Dmean: 3D, 166.0 Gy; IMRT, 185.1 Gy, and proton therapy, 191.3 Gy; p < 0.001) (Figure S1b). The use of modern RT techniques (IMRT or proton therapy, HF or ultra-HF, and higher dose) had increased in more recent years (Figure S2). Table 1 summarizes patient characteristics.
### Table 1. Clinical and treatment characteristics of all patients (n = 1573).

| Characteristics                  | No. | %   |
|----------------------------------|-----|-----|
| **Age (year)**                   |     |     |
| ≤70                              | 592 | 39.9|
| >70                              | 981 | 60.1|
| **Treatment year**               |     |     |
| 2005                             | 53  | 3.4 |
| 2006                             | 101 | 6.4 |
| 2007                             | 143 | 9.1 |
| 2008                             | 125 | 7.9 |
| 2009                             | 95  | 6.0 |
| 2010                             | 132 | 8.4 |
| 2011                             | 161 | 10.2|
| 2012                             | 200 | 12.7|
| 2013                             | 205 | 13.0|
| 2014                             | 199 | 12.7|
| 2015                             | 155 | 9.9 |
| 2016                             | 4   | 0.3 |
| T1                               | 216 | 12.1|
| T2                               | 680 | 39.6|
| **T stage**                      |     |     |
| T3                               | 618 | 42.7|
| T4                               | 56  | 5.4 |
| Tx                               | 3   | 0.3 |
| **Gleason score**                |     |     |
| ≤6                               | 464 | 29.6|
| 7                                | 515 | 32.7|
| 8                                | 346 | 22.0|
| ≥9                               | 241 | 15.3|
| Unknown                          | 7   | 0.4 |
| **Initial PSA (ng/mL)**          |     |     |
| <10                              | 674 | 43.1|
| 10–20                            | 366 | 23.4|
| >20                              | 525 | 33.5|
| Low                              | 177 | 9.8 |
| **NCCN risk group**              |     |     |
| Intermediate                     | 408 | 22.9|
| High                             | 761 | 43.1|
| Very high                        | 227 | 12.9|
| **D’Amico risk group**           |     |     |
| Low                              | 177 | 11.3|
| Intermediate                     | 383 | 24.3|
| High                             | 1013| 64.4|
| **AUA risk group**               |     |     |
| Low                              | 177 | 11.3|
| Intermediate                     | 539 | 34.3|
| High                             | 857 | 54.5|
| **CPG risk group**               |     |     |
| Low                              | 178 | 11.3|
| Intermediate                     | 407 | 25.9|
| High                             | 366 | 23.3|
| Very high                        | 622 | 39.5|
| No                               | 543 | 34.5|
| Before RT                        | 210 | 13.4|
| **ADT**                          |     |     |
| Before/concurrent RT             | 747 | 47.5|
| Concurrent RT                    | 27  | 1.7 |
| Post-RT                          | 46  | 2.9 |
| Prostate (±SV)                   | 1020| 64.8|
| **RT volume**                    |     |     |
| Whole pelvis                     | 534 | 33.9|
| Half pelvis                      | 8   | 0.5 |
| Unknown                          | 11  | 0.7 |
| **RT modality**                  |     |     |
| Proton therapy                   | 44  | 2.8 |
| 3D + IMRT                        | 21  | 1.3 |
| Unknown                          | 11  | 0.7 |
Table 1. Cont.

| Characteristics            | No. | %   |
|----------------------------|-----|-----|
| RT dose scheme             |     |     |
| CF                         | 692 | 44.0|
| HF                         | 738 | 46.9|
| Ultra-HF                   | 143 | 9.1 |
| Fractional dose (Gy)       |     |     |
| Median 2.2 (1.7–7.5)       |     |     |
| Total dose (Gy)            |     |     |
| Median 72.6 (35.0–81.0)    |     |     |
| Total dose in BED (Gy1.5)  |     |     |
| Median 179.1 (107.3–225.0) |     |     |

PSA, Prostate-Specific Antigen; NCCN, National Comprehensive Cancer Network; AUA, American Urological Association; CPG, Cambridge Prognostic Group; ADT, Androgen deprivation therapy; RT, Radiotherapy; SV, Seminal vesicle; 3D CRT, 3-dimensional conformal radiotherapy; IMRT, Intensity-modulated radiotherapy; CF, conventional fractionation; HF, hypofractionation; Ultra-HF, ultra-hypofractionation; BED, Biologically effective dose; conventional fractionation: 1.8–2 Gy per fraction, moderate hypofractionation: >2 Gy per fraction, ultra-hypofractionation: ≥5 Gy per fraction.

3.2. Treatment Outcomes and Risk Stratification

The median follow-up was 75 (36–239) months from the first diagnosis. The 5- and 10-year rates were as follows (Figure 1): BCFFS; 82.4%, 59.8%, respectively. OS; 95.4%, 82.8%, respectively. Cause-specific survival rates; 98.8%, 96.6%, respectively. Of 148 deaths, most were age-related, 33 were disease-related. At a median of 46 (2–211) months after the first diagnosis, 19.3% of patients developed BCF events, with/without clinical recurrence. Table S2 shows details of recurrence patterns.

![Figure 1. Kaplan–Meier survival curves of biochemical failure (BCF)-free survival, overall survival (OS), and cause-specific survival rates in all patients.](image)

AUC values for BCFFS rates were highest with NCCN risk classification (0.556, 95% confidence interval (CI): 0.524–0.588; p < 0.001), followed by AUA, CPG, and D’Amico (Figure 2a). All risk-stratification tools differentiated BCFFS rates (Figure 2b) and cause-specific survival rates (Figure 2c) significantly. OS rates were not significantly different in all risk groups (NCCN: p = 0.387, hazard ratio (HR) = 1.085, 95% CI = 0.902–1.305; D’Amico: p = 0.576, HR = 1.121, 95% CI = 0.885–1.420; AUA: p = 0.589, HR = 1.097, 95% CI = 0.868–1.386; CPG: p = 0.712, HR = 1.070, 95% CI = 0.918–1.246). Appendix A summarizes the BCFFS, BCF, OS, and cause-specific survival rates in each NCCN risk group.
Figure 2. Cont.
Figure 2. (a) Receiver operating characteristic curves for each risk-stratification tool as a predictor of biochemical failure (BCF)-free survival, and (b) BCF-free survival and (c) cause-specific survival rates according to risk groups stratified using four different classification tools (NCCN, D'Amico, AUA, and CPG guidelines). AUA, American Urological Association; CPG, Cambridge Prognostic Groups; NCCN, National Comprehensive Cancer Network. * denotes statistically significant p value.

3.3. Prognostic Factors in Each NCCN Risk Group

Univariate and multivariate analyses for BCFFS in all patients revealed that Gleason score, initial PSA <12 ng/mL, RT modality (IMRT/proton), and RT dose $\geq 179 \text{ Gy}_{1.5}$ were independent significant factors ($p; 0.016, <0.001, 0.036, 0.022$, respectively) (Table 2). BED and BCFFS showed a significant linear relationship ($p = 0.026$), with 179 $\text{ Gy}_{1.5}$ (equivalent dose in 2 Gy fractions (EQD2), 77 Gy)) as the most significant cutoff. After propensity score matching according to RT technique (3D vs. IMRT/proton), no RT-related factors were significant for BCFFS. Only Gleason score, initial PSA, and ADT were independent significant factors ($p < 0.001, 0.003, <0.001$, respectively). Patient characteristics of the matched groups are shown in Table S3, and the results of the analyses are shown in Table S4.
Table 2. Results of univariate and multivariate analyses for biochemical failure-free survival in all patients.

| Variable                        | Univariate Analysis | Multivariate Analysis |
|---------------------------------|---------------------|-----------------------|
|                                 | HR (95% CI)         | p Value               | HR (95% CI)         | p Value               |
| Age (continuous)                | 0.995 (0.981–1.008) | 0.430                 |                      |                      |
| Age (>70 vs. ≤70)               | 0.966 (0.793–1.177) | 0.730                 |                      |                      |
| Age (>60 vs. ≤60)               | 0.897 (0.634–1.269) | 0.539                 |                      |                      |
| T stage                         |                     |                       |                      |                      |
| T3 vs. T1                       | 1.142 (1.015–1.285) | 0.027                 | 0.817 (0.601–1.111) | 0.198                 |
| T2, T3, T4 vs. T1               | 1.389 (1.035–1.864) | 0.029                 |                      |                      |
| Gleason score                   |                     |                       |                      |                      |
| ≥9 vs. <9                       | 1.160 (1.071–1.256) | <0.001                | 1.359 (1.058–1.746) | 0.016                 |
| ≥9 vs. ≤6                       | 1.783 (1.332–2.386) | <0.001                |                      |                      |
| ≥7–8 vs. <6                     | 1.303 (1.033–1.644) | 0.025                 |                      |                      |
| initial PSA                     | 1.004 (1.002–1.006) | <0.001                |                      |                      |
| ≥12 vs. <12                     | 1.637 (1.343–1.996) | <0.001                | 1.508 (1.227–1.854) | <0.001                |
| ADT combination (Yes vs. No)    | 0.744 (0.612–0.905) | 0.003                 |                      |                      |
| RT volume                       | 0.970 (0.866–1.087) | 0.604                 |                      |                      |
| IMRT/Proton vs. 3D              | 0.719 (0.586–0.881) | 0.001                 | 0.761 (0.589–0.983) | 0.036                 |
| Proton vs. 3D/IMRT              | 1.036 (0.644–1.666) | 0.885                 |                      |                      |
| RT dose scheme                  |                     |                       |                      |                      |
| CF vs. HF/ultra-HF              | 1.346 (1.104–1.641) | 0.003                 | 0.773 (0.512–1.166) | 0.220                 |
| HF vs. CF                       | 0.723 (0.585–0.893) | 0.003                 |                      |                      |
| Ultra-HF vs. CF                 | 0.840 (0.585–1.205) | 0.343                 |                      |                      |
| HF vs. ultra-HF                 | 0.861 (0.592–1.252) | 0.433                 |                      |                      |
| Total dose, BED (Gy 1.5) (continuous) | 0.993 (0.988–0.999) | 0.026                 |                      |                      |
| BED ≥179 Gy 1.5 vs. <179 Gy 1.5 | 0.701 (0.575–0.853) | <0.001                | 0.644 (0.441–0.939) | 0.022                 |

HR, Hazard ratio; CI, Confidence Interval; ADT, Androgen deprivation therapy; RT, Radiotherapy; SV, Seminal vesicle; 3D CRT, 3-dimensional conformal radiotherapy; IMRT, Intensity-modulated radiotherapy; CF, conventional fractionation; HF, hypofractionation; BED, Biologically effective dose; conventional fractionation: 1.8–2 Gy per fraction, moderate hypofractionation: >2 Gy per fraction, ultra-hypofractionation: ≥5 Gy per fraction.

NCCN low-risk group: No significant prognostic factor for BCFFS or OS was identified, and no significant impact of a higher dose was observed. NCCN intermediate-risk group: ADT combination, HF/ultra-HF, and ≥170 Gy 1.5 (EQD2, 72 Gy) were significant favorable factors for BCFFS in univariate analysis (p = 0.028, HR = 0.606, 95% CI = 0.388–0.947). On the other hand, there was no significant factor for OS in both univariate and multivariate analyses. NCCN high-risk group: ADT (p < 0.001, HR = 0.505, 95% CI = 0.379–0.672), IMRT/proton therapy (p = 0.014, HR = 0.638, 95% CI = 0.446–0.915), and ≥179 Gy 1.5 (p = 0.009, HR = 0.503, 95% CI = 0.300–0.844) were independent significant factors for BCFFS in both univariate and multivariate analyses. For OS, although IMRT/proton therapy (p < 0.001, HR = 0.367, 95% CI = 0.226–0.596), CF (p = 0.002, HR = 2.271, 95% CI = 1.353–3.811), and ≥179 Gy 1.5 (p = 0.003, HR = 0.466, 95% CI = 0.282–0.770) were significant factors in univariate analysis, none was significant in multivariate analysis. NCCN very-high-risk group: Gleason score and HF/ultra-HF were significant factors for BCFFS in univariate analysis (p = 0.019, 0.038, respectively), but not in multivariate analysis. Similarly, no factor was significant in univariate and multivariate analyses for OS. Similar results were shown even after propensity score matching (Table S4).

3.4. Radiotherapy-Related Factors

RT comprising IMRT, HF, and higher dose (≥179 Gy 1.5) was administered to 829 (53%) patients. BCFFS and OS rates significantly improved in these patients (p = 0.003, 0.002, respectively) (Figure 3a). Cause-specific survival rates did not have significant differences (p = 0.288). Following patient subgrouping (NCCN classification), this triple
combination (IMRT + HF + \( \geq 179 \text{ Gy}_{1.5} \)) elicited a significant impact on BCFFS in the NCCN intermediate- and high-risk groups \((p = 0.048, 0.028, \text{ respectively})\). HR for BCFFS was largest in the NCCN high-risk group (Figure 3b, Table 3). Also, this combination decreased BCF rates significantly in NCCN intermediate-, high-, and very-high-risk groups \((p = 0.004, 0.010, 0.007, \text{ respectively})\): the HR for BCF rate was largest in the NCCN high-risk group (Table 3). This combination significantly increased OS rate only in the NCCN high-risk group \((p = 0.006, \text{ HR} = 0.477, 95\% \text{ CI} = 0.279–0.815)\) (Figure 3c).

Figure 3. Cont.
3.5. Toxicities

Radiation-related toxicity (≥grade II) rates were acceptable (acute GU, 10.7%; acute GI, 6.2%; late GU, 13.4%; late GI, 6.5%). There was no significant increase in toxicity in patients with a longer follow-up duration (Table S5). Multivariate analysis revealed that acute GU toxicity (≥grade II) incidences decreased significantly with ultra-HF (CF, 10.1%; HF, 13%; ultra-HF, 1%; p = 0.006) and IMRT (10% vs. 13%, p = 0.054). Acute GI toxicity (≥grade II) incidences increased significantly with WPRT (11% vs. 4%, p < 0.001). Late GU toxicity (≥grade II) incidences were significantly higher with HF than with CF (19% vs. 8%, p = 0.035) and with WPRT than with prostate-only RT (22% vs. 9%, p < 0.001). IMRT/HF/dose escalation did not increase grade III toxicities.
IMRT + HF + higher dose (≥179 Gy\textsubscript{1.5}) had the following toxicity (≥grade II) rates: acute GU, 15.3%; acute GI, 7.9%; late GU, 22.7%; late GI, 6.3%. The late GU toxicity rate was higher than that in all patients. Most events were grade II, and the grade III toxicity rates were similar (Table S6).

4. Discussion

Our study showed a significant linear relationship between total radiation dose and BCFFS with 179 Gy\textsubscript{1.5} (EQD2, 77 Gy) as the most significant cutoff. Dose escalation prominently benefited the high-risk group. In the intermediate-risk group, modest doses over 170 Gy\textsubscript{1.5} (EQD2, 72 Gy) delivered significantly better outcomes. IMRT + dose escalation + HF resulted in 5-year BCFFS rates of 80–90% in all risk groups; the improvement in BCFFS translated into survival benefits in the high-risk group. Although HF increased the late GU toxicity rate, IMRT/HF/dose escalation did not increase grade III toxicities. The combination of contemporary RT techniques did not increase acute/late toxicities significantly.

This study holds both similarities and differences from existing studies. We predominantly analyzed RT-related factors in each risk group to derive conclusions for application in clinical practice. Before analyses, patients were classified into low-, intermediate-, and high-risk groups (NCCN classification). Consistent with previous reports, we confirmed that dose escalation benefited BCF, most prominently in the high-risk group. Higher RT dose did not increase ≥grade 2 RT-related toxicities. However, given the risk of toxicities, our data suggested using only moderate doses for low/intermediate-risk groups. Dose escalation was a significant factor for OS in the high-risk group, but not in multivariate analysis. However, together with IMRT and HF, dose escalation may be more effective, even at improving survival. It should not be forgotten that modern RT techniques have prognostic meaning when enabling dose escalation. Ultimately, the use of contemporary techniques may increase survival gains with intensified and risk-adapted RT.

Standard options for the initial management for localized prostate cancer include RT (EBRT and/or brachytherapy with or without ADT), radical prostatectomy, or active surveillance in select patient populations. In clinical practice, the choice of treatment is determined by various factors, including risk stratification, patient preference, clinicians’ judgment, and resource availability [1,2]. Based on NCCN guidelines [4], EBRT is a definitive initial treatment option in low-, intermediate-, and high-risk patients. EBRT may be considered post-surgery if there is a high risk of recurrence based on surgical pathology, increase in PSA levels during follow-up, or detection of local recurrence. Although there are no randomized trials comparing RT with radical prostatectomy yet, trials completed to date and observational data suggest that outcomes with either EBRT or brachytherapy are similar to those with radical prostatectomy when men with clinically localized prostate cancer are stratified based on clinical tumor (T) stage, pretreatment PSA, and Gleason score.

Various risk-stratification tools exist for selecting treatments for prostate cancer, and dividing patients into subgroups according to major risk factors to predict BCFs is recommended, and similarities between tools are evident [3–7]. The superiority of each tool for predicting prostate cancer-related deaths is unclear. In a recently published study, which used the Prostate Cancer database in Sweden [26], a population-based research database including both untreated and treated patients followed for prostate cancer-related deaths for up to 19 years, a total of nine pretreatment risk stratification tools were compared. The MSKCC nomogram (C-index: 0.81, 95% CI = 0.80–0.81), CAPRA score (C-index: 0.80, 95% CI = 0.79–0.81), and CPG system (C-index: 0.78, 95% CI = 0.78–0.79) exhibited the best performance for discriminating prostate cancer-related deaths. However, complete information on all variables used in the risk stratification tools were only available for 35% of the cohort. Furthermore, information on cT2 to T3 substages was not recorded in the database. In our nationwide database, we demonstrated that the NCCN system exhibited the highest AUC value for BCFFS, although the other classification systems demonstrated
comparable significance. Future well-controlled studies with a larger sample size and long-term follow-up are warranted to identify the superiority of the different tools.

Various fractionation and dose regimens can be considered for RT depending on clinical conditions. The irradiated dose for definitive RT in localized prostate cancer was 70 Gy or lower in the past, but there have been attempts to improve treatment outcomes by increasing the radiation dose. Retrospective studies [8–11] reported increased BCFFS and OS rates with dose escalations. Randomized trials [10,13–19] reported significantly lower biochemical/clinical failure rates in the higher-dose arms than in the lower-dose arms. Nevertheless, these studies revealed greater late GI/GU toxicity rates with higher RT dose arm than in the lower-dose arm. Furthermore, although dose escalation significantly reduced BCFs, no improvements in OS were noted. A major limitation is that the therapeutic ratio of tumor control versus previously reported toxicity is less applicable at present given the employment of more modern treatment methods.

Multiple randomized trials and a meta-analysis evaluated the role of hypofractionated RT and concluded that its efficacy is equivalent to that of CF [27–35]. Data on whether HF increases overall treatment-related toxicity are inconclusive. Most trials [28–30,33] reported a small increase in acute GI toxicity risk. Two studies [34,35] identified a notable increase in late toxicity risk. A 2019 Cochrane review of 10 randomized trials concluded that the effects of HF on late GI toxicity were unclear and that there was little to no difference in acute/late GU toxicity [31]. Although the optimal regimen for HF remains unestablished, the AUA/ASTRO/ASCO guidelines [24] endorsed either 60 Gy/20 fractions or 70 Gy/28 fractions; most evidence supported these regimens. In our study, the most frequently selected schedule was 2.1–2.2 Gy/fraction or 2.5–2.6 Gy/fraction, although there were substantial differences between institutions. The total dose increased with an increase in dose/fraction, indicating that HF is useful for administering higher doses. Subsequent studies will help determine the optimal schedule to deliver higher RT doses.

Ultra-HF, also called stereotactic body radiation therapy (SBRT), is an appropriate alternative to CF RT in low/intermediate-risk prostate cancer patients who do not require nodal irradiation. Several prospective trials reported favorable efficacy and toxicities of ultra-HF [36–39]. Nevertheless, median follow-up time has generally been limited to 3–5 years, and there is concern regarding long-term outcomes and higher late GU toxicity with SBRT vs. IMRT. SBRT has not been directly compared with moderate HF. We were unable to demonstrate the benefits of HF over CF in BCFFS or BCF rates using multivariate analyses of the entire cohort. The significance of HF was larger in the intermediate- and high-risk groups than in the others. Therefore, radiation dose is a more important prognostic factor than fractionation schedule. Like previous reports, ultra-HF and HF increased acute and late GU toxicities (≥grade II), respectively. Thus, long-term follow-up and careful patient monitoring are necessary.

Our study has several limitations. First, no significant difference was identified in prognosis between the favorable and unfavorable intermediate-risk groups (data not shown). A potential reason was that “<50% positive cores,” the diagnostic criteria for the favorable intermediate-risk group, could not be identified in our retrospective database. As the classification of favorable and unfavorable groups was developed recently, precise classification of patients diagnosed in the past was difficult. Second, the omission or duration of ADT may not have reflected the modern standard of care for unfavorable intermediate- and high-risk patients. Further, salvage therapy was initiated at the clinician’s discretion, distinct to a standardized threshold. However, since we aimed to propose an optimal RT strategy, ADT-related analyses were not performed in detail. Third, it is necessary to demonstrate survival benefits or changes in long-term side effects via long-term follow-up, because disease-related events may occur even 5 and 10 years after diagnosis in prostate cancer patients. Therefore, a longer follow-up is essential to obtain solid conclusions with sufficient evidence to change clinical practice.
5. Conclusions

EBRT treats localized prostate cancer effectively. Also, the prognostic utility of NCCN risk grouping was validated in our nationwide cohort study. HF and IMRT may effectively deliver higher doses without significantly increasing severe toxicities. In the high-risk group, radiation dose escalation with modern high-precision RT techniques effectively increased survival rates, but not in the low-risk group. Risk-adapted RT (more intense RT, high-risk patients; moderate-dose RT, low-risk patients) can be considered, although further prospective, long-term follow-up studies are warranted.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13112732/s1, Figure S1: Distribution of total dose in biologically effective dose (BED) against different fractional doses (a) or different radiotherapy (RT) modalities (b), Figure S2: Temporal trends according to treatment year on specific radiotherapy (RT) techniques: (a) patients with intensity-modulated RT (IMRT) or proton therapy vs. 3-dimensional conformal RT, (b) patients with hypofractionation (HF) or ultra-HF vs. conventional fractionation (CF) RT, (c) patients with higher RT dose ($\geq 179 \text{ Gy}_{1.5}$) vs. lower RT dose ($<179 \text{ Gy}_{1.5}$), and (d) patients with combined RT-related factors (IMRT, HF, and higher dose ($\geq 179 \text{ Gy}_{1.5}$)), Table S1: Prostate cancer risk stratification criteria for different risk-grouping systems, Table S2: Summary of treatment outcomes, Table S3: Toxicity rates stratified by RTOG radiation toxicity criteria in all patients ($n = 1573$), Table S4: Toxicity rates stratified by RTOG radiation toxicity criteria in patients treated with a combination of three factors (intensity-modulated radiotherapy (IMRT), hypofractionation, and higher dose ($\geq 179 \text{ Gy}_{1.5}$)) ($n = 829$).

Author Contributions: Study concept and design: S.H.C., Y.S.K., W.P., J.C. Visualization: S.H.C., J.C. Data acquisition: S.H.C., Y.S.K., J.Y., T.-K.N., J.-S.K., B.-S.J., J.H.K (Jin Ho Kim), Y.K., B.K.J., A.R.C., Y.-H.P., S.U.L., K.H.C., J.H.K (Jin Hee Kim), H.K., Y.C., Y.J.K., D.S.L., Y.J.S., S.J.S., W.P. and J.C. Data analysis and interpretation: S.H.C., Y.S.K., W.P., J.C. Manuscript preparation: S.H.C., Y.S.K. Critical revision: K.H.C., W.P., J.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The Korean Radiation Oncology Group (KROG) authorized and cooperated with this study (named “KROG 18-15”). The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of each participating hospital approved by KROG 18-15.

Informed Consent Statement: Since the current study was retrospective, the need for written informed consent was waived.

Data Availability Statement: Data sharing is not applicable to this article.

Conflicts of Interest: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.

Appendix A

Based on the National Comprehensive Cancer Network (NCCN) guidelines, the 5- and 10-year biochemical failure-free survival rates were 91.6% and 75.4% in the low-risk group, 83.7% and 65.3% in the intermediate-risk group, 80.6% and 54.7% in the high-risk group, and 77.1% and 51.9% in the very-high-risk group, respectively. The actual biochemical failure rates were 8.5%, 15.4%, 22.1%, and 25.6% in the low-, intermediate-, high-, and very-high-risk groups, respectively. The 5- and 10-year overall survival rates were 91.6% and 75.4% in the low-risk group, 83.7% and 65.3% in the intermediate-risk group, 80.6% and 54.7% in the high-risk group, and 77.1% and 51.9% in the very-high-risk group, respectively. The 5- and 10-year cause-specific survival rates were all 100% in the low-risk group, 99.7% and 98.8% in the intermediate-risk group, 98.7% and 95.3% in the high-risk group, and 96.4% and 93.6% in the very-high-risk group, respectively.
References

1. Roach, M., 3rd; Ceron Lizarraga, T.L.; Lazar, A.A. Radical prostatectomy versus radiation and androgen deprivation therapy for clinically localized prostate cancer: How good is the evidence? Int. J. Radiat. Oncol. Biol. Phys. 2015, 93, 1064–1070. [CrossRef]

2. Hamdy, F.C.; Donovan, J.L.; Lane, J.A.; Mason, M.; Metcalfe, C.; Holding, P.; Davis, M.; Peters, T.J.; Turner, E.L.; Martin, R.M.; et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 2016, 375, 1415–1424. [CrossRef]

3. D’Amico, A.V.; Whittington, R.; Malkowicz, S.B.; Schultz, D.; Blank, K.; Broderick, G.A.; Tomaszewski, J.E.; Renshaw, A.A.; Kaplan, I.; Beard, C.J.; et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280, 969–974. [CrossRef]

4. Mohler, J.L.; Antonarakis, E.S.; Armstrong, A.J.; D’Amico, A.V.; Davis, B.J.; Dorff, T.; Eastham, J.A.; Enke, C.A.; Farrington, T.A.; Higano, C.S.; et al. Prostate cancer, version 2.2019, nccn clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2019, 17, 479–505. [CrossRef] [PubMed]

5. Sanda, M.G.; Cadeddu, J.A.; Kirkby, E.; Chen, R.C.; Crispino, T.; Fontanarosa, J.; Freedland, S.; Green, K.; Klotz, L.H.; Makarov, D.V.; et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: Risk stratification, shared decision making, and care options. J. Urol. 2018, 199, 683–690. [CrossRef] [PubMed]

6. GnanaPragasam, V.J.; Lophatananon, A.; Wright, K.A.; Muir, K.R.; Gavin, A.; Greenberg, D.C. Improving clinical risk stratification at diagnosis in primary prostate cancer: A prognostic modelling study. PLoS Med. 2016, 13, e1002063. [CrossRef] [PubMed]

7. Mottet, N.; Bellmunt, J.; Bolla, M.; Briërs, E.; Cumberbatch, M.G.; De Santis, M.; Fossati, N.; Gross, T.; Henry, A.M.; Joniau, S.; et al. EAU-estro-sio guidelines on prostate cancer. Part I: Screening, diagnosis, and local treatment with curative intent. Eur. Urol. 2017, 71, 618–629. [CrossRef]

8. Eade, T.N.; Hanlon, A.L.; Horwitz, E.M.; Buyyounouski, M.K.; Hanks, G.E.; Pollack, A. What dose of external-beam radiation is high enough for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 2007, 68, 682–689. [CrossRef]

9. Jacob, R.; Hanlon, A.L.; Horwitz, E.M.; Movsas, B.; Uzzo, R.G.; Pollack, A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004, 100, 538–543. [CrossRef]

10. Pollack, A.; Smith, L.G.; von Eschenbach, A.C. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 507–512. [CrossRef]

11. Zelefsky, M.J.; Fuks, Z.; Hunt, M.; Lee, H.J.; Lombardi, D.; Ling, C.C.; Reuter, V.E.; Venkatraman, E.S.; Leibel, S.A. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J. Urol. 2001, 166, 876–881. [CrossRef]

12. Pollack, A.; Zagars, G.K.; Smith, L.G.; Lee, J.J.; von Eschenbach, A.C.; Antolak, J.A.; Starkschall, G.; Rosen, I. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J. Clin. Oncol. 2000, 18, 3904–3911. [CrossRef]

13. Kuban, D.A.; Tucker, S.L.; Dong, L.; Starkschall, G.; Huang, E.H.; Cheung, M.R.; Lee, A.K.; Pollack, A. Long-term results of the m. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70, 67–74. [CrossRef]

14. Zietman, A.L.; Bae, K.; Slater, J.D.; Shipley, W.U.; Efstathiou, J.A.; Coen, J.J.; Bush, D.A.; Lunt, M.; Spiegel, D.Y.; Skowronski, R.; et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/american college of radiology 95-09. J. Clin. Oncol. 2010, 28, 1106–1111. [CrossRef]

15. Zietman, A.L.; DeSilvio, M.L.; Slater, J.D.; Rossi, C.J., Jr.; Miller, D.W.; Adams, J.A.; Shipley, W.U. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005, 294, 1233–1239. [CrossRef] [PubMed]

16. Al-Mamgani, A.; van Putten, W.L.; Heemsbergen, W.D.; van Leenders, G.J.; Slot, A.; DieIwalt, M.F.; Incrocci, L.; Lebesque, J.V. Update of dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72, 980–988. [CrossRef] [PubMed]

17. Heemsbergen, W.D.; Al-Mamgani, A.; Slot, A.; DieIwalt, M.F.; Lebesque, J.V. Long-term results of the dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother. Oncol. 2014, 110, 104–109. [CrossRef] [PubMed]

18. Beckendorf, V.; Guerif, S.; Le Prise, E.; Cosset, J.M.; Bougnoux, A.; Chauvet, B.; Salem, N.; Chapet, O.; Bourdain, S.; Bachaud, J.M.; et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of getug 06 randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80, 1056–1063. [CrossRef]

19. Michalski, J.M.; Moughan, J.; Purdy, J.; Boschi, W.; Brunner, D.W.; Bahary, J.P.; Lau, H.; Duclos, M.; Parliament, M.; Morton, G.; et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The nrg oncology rtoG 0126 randomized clinical trial. JAMA Oncol. 2018, 4, e180039. [CrossRef]

20. Sheets, N.C.; Goldin, G.H.; Meyer, A.M.; Wu, Y.; Chang, Y.; Sturmer, T.; Holmes, J.A.; Reeve, B.B.; Godley, P.A.; Carpenter, W.R.; et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 2012, 307, 1611–1620. [PubMed]
21. Michalski, J.M.; Yan, Y.; Watkins-Bruner, D.; Bosch, W.R.; Winter, K.; Galvin, J.M.; Bahary, J.P.; Morton, G.C.; Parliament, M.B.; Sandler, H.M. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the radiation therapy oncology group 0126 prostate cancer trial. *Int. J. Radiat. Oncol. Biol. Phys.* 2013, 87, 932–938. [CrossRef]

22. Zelefsky, M.J.; Levin, E.J.; Hunt, M.; Yamada, Y.; Shippy, A.M.; Jackson, A.; Amols, H.I. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 2008, 70, 1124–1129. [CrossRef]

23. Brenner, D.J.; Hall, E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. *Int. J. Radiat. Oncol. Biol. Phys.* 1999, 43, 1095–1101. [CrossRef]

24. Morgan, S.C.; Hoffman, K.; Loblaw, D.A.; Buyoumouski, M.K.; Patton, C.; Barocas, D.; Bentzen, S.; Chang, M.; Efthathiou, J.; Greany, P.; et al. Hypofractionated radiotherapy for localized prostate cancer: An astro, asco, and aua evidence-based guideline. *J. Clin. Oncol.* 2018. [CrossRef]

25. Web-R. Available online: http://web-r.org/ (accessed on 31 May 2021).

26. Zelic, R.; Garmo, H.; Zugna, D.; Stattin, P.; Richardi, L.; Akre, O.; Pettersson, A. Predicting prostate cancer death with different pretreatment risk stratification tools: A head-to-head comparison in a nationwide cohort study. *Eur. Urol.* 2020, 77, 180–188. [CrossRef]

27. Lee, W.R.; Dignam, J.J.; Amin, M.B.; Bruner, D.W.; Low, D.; Swanson, G.P.; Shah, A.B.; D’Souza, D.P.; Michalski, J.M.; Dayes, I.S.; et al. Randomized phase iii noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. *J. Clin. Oncol.* 2016, 34, 2325–2332. [CrossRef]

28. Catton, C.N.; Lukka, H.; Gu, C.S.; Martin, J.M.; Supiot, S.; Chung, P.W.M.; Bauman, G.S.; Bahary, J.P.; Ahmed, S.; Cheung, P.; et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. *J. Clin. Oncol.* 2017, 35, 1884–1890. [CrossRef]

29. Dearmally, D.; Syndikus, I.; Mossop, H.; Khoo, V.; Birtle, A.; Bloomfield, D.; Graham, J.; Kirkbride, P.; Logue, J.; Malik, Z.; et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 chhip trial. *Lancet Oncol.* 2016, 17, 1047–1060. [CrossRef]

30. Pollack, A.; Walker, G.; Horwitz, E.M.; Price, R.; Feigenberg, S.; Konski, A.A.; Movsas, B.; Greenberg, R.E.; Uzzo, R.G.; et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. *J. Clin. Oncol.* 2013, 31, 3860–3868. [CrossRef] [PubMed]

31. Hickey, B.E.; James, M.L.; Daly, T.; Soh, F.Y.; Jeffery, M. Hypofractionation for clinically localized prostate cancer. *Cochrane Database Syst. Rev.* 2019, 9, CD0011462. [CrossRef] [PubMed]

32. Avkshtol, V.; Ruth, K.J.; Ross, E.A.; Hallman, M.A.; Greenberg, R.E.; Price, R.A., Jr.; Leachman, B.; Uzzo, R.G.; Ma, C.; Chen, D.; et al. Ten-year update of a randomized, prospective trial of conventional fractionated versus moderate hypofractionated radiation therapy for localized prostate cancer. *J. Clin. Oncol.* 2020, 38, 1676–1684. [CrossRef] [PubMed]

33. Aluwini, S.; Pos, F.; Schimmel, E.; van Lin, E.; Krol, S.; van der Toorn, P.P.; de Jager, H.; Heijmen, B.; et al. Hypofractionation versus conventionally fractionated radiotherapy for patients with prostate cancer (hypro): Acute toxicity results from a randomised non-inferiority phase 3 trial. *Lancet Oncol.* 2015, 16, 274–283. [CrossRef]

34. Bruner, D.W.; Pugh, S.L.; Lee, W.R.; Hall, W.A.; Dignam, J.J.; Low, D.; Swanson, G.P.; Shah, A.B.; Malone, S.; Michalski, J.M.; et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: A phase 3 randomized clinical trial. *JAMA Oncol.* 2019, 5, 664–670. [CrossRef] [PubMed]

35. Incrocci, L.; Wortel, R.C.; Alemayehu, W.G.; Aluwini, S.; Schimmel, E.; Krol, S.; van der Toorn, P.P.; Jager, H.; Heemsbergen, W.; Heijmen, B.; et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (hypro): Final efficacy results from a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol.* 2016, 17, 1061–1069. [CrossRef]

36. Widmark, A.; Gunnlaugsson, A.; Beckman, L.; Thellenberg-Karlsson, C.; Hoyer, M.; Lagerlund, M.; Kindblom, J.; Ginman, C.; Johannson, B.; Bjornling, K.; et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the hypo-rt-p randomised, non-inferiority, phase 3 trial. *Lancet Oncol.* 2019, 20, 385–395. [CrossRef]

37. Brand, D.H.; Tree, A.C.; Ostler, P.; van der Voet, H.; Loblaw, A.; Chu, W.; Ford, D.; Tolani, S.; Jain, S.; Martin, A.; et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (pace-b): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. *Lancet Oncol.* 2019, 20, 1531–1543. [CrossRef]

38. King, C.R.; Freeman, D.; Kaplan, I.; Fuller, D.; Bolzicco, G.; Collins, S.; Meier, R.; Wang, J.; Kupelian, P.; Steinberg, M.; et al. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase ii trials. *Radiat. Oncol.* 2013, 109, 217–221. [CrossRef]

39. Lehrer, E.J.; Kishan, A.U.; Yu, J.B.; Trifiletti, D.M.; Showalter, T.N.; Ellis, R.; Zaorsky, N.G. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase iii randomized trials. *Radiat. Oncol.* 2020, 148, 235–242. [CrossRef]